PL374019A1 - Pochodne benzoksazyny jako modulatory 5-HT6 i ichzastosowanie - Google Patents

Pochodne benzoksazyny jako modulatory 5-HT6 i ichzastosowanie

Info

Publication number
PL374019A1
PL374019A1 PL03374019A PL37401903A PL374019A1 PL 374019 A1 PL374019 A1 PL 374019A1 PL 03374019 A PL03374019 A PL 03374019A PL 37401903 A PL37401903 A PL 37401903A PL 374019 A1 PL374019 A1 PL 374019A1
Authority
PL
Poland
Prior art keywords
sup
modulators
benzoxazine derivatives
compounds
formula
Prior art date
Application number
PL03374019A
Other languages
English (en)
Other versions
PL211057B1 (pl
Inventor
Jacob Berger
Robin Douglas Clark
Shu-Hai Zhao
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL374019A1 publication Critical patent/PL374019A1/pl
Publication of PL211057B1 publication Critical patent/PL211057B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Wynalazek dotyczy związków o wzorze (I), w którym R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, Y, Z<sup>1</sup>, m, n i p mają znaczenie podane w opisie, oraz ich farmaceutycznie dopuszczalnych soli i proleków wykazujących powinowactwo do receptora 5-HT6. Wynalazek dotyczy także środków zawierających te związki, sposobów stosowania i sposobów wytwarzania związków o wzorze (I).
PL374019A 2002-05-13 2003-05-05 Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny PL211057B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37800302P 2002-05-13 2002-05-13

Publications (2)

Publication Number Publication Date
PL374019A1 true PL374019A1 (pl) 2005-09-19
PL211057B1 PL211057B1 (pl) 2012-04-30

Family

ID=29420358

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374019A PL211057B1 (pl) 2002-05-13 2003-05-05 Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny

Country Status (36)

Country Link
US (4) US6867204B2 (pl)
EP (1) EP1506179B1 (pl)
JP (1) JP4307377B2 (pl)
KR (1) KR100636475B1 (pl)
CN (1) CN100429206C (pl)
AR (1) AR039988A1 (pl)
AT (1) ATE316523T1 (pl)
AU (1) AU2003233231B2 (pl)
BR (1) BRPI0310032B8 (pl)
CA (1) CA2485136C (pl)
DE (1) DE60303376T2 (pl)
DK (1) DK1506179T3 (pl)
EA (1) EA009982B1 (pl)
EC (1) ECSP045420A (pl)
EG (1) EG25683A (pl)
ES (1) ES2256744T3 (pl)
GT (1) GT200300108A (pl)
HR (1) HRP20041030B1 (pl)
IL (1) IL164928A0 (pl)
JO (1) JO2413B1 (pl)
MA (1) MA27118A1 (pl)
MX (1) MXPA04011254A (pl)
MY (1) MY139612A (pl)
NO (1) NO329380B1 (pl)
NZ (1) NZ536230A (pl)
PA (1) PA8573501A1 (pl)
PE (1) PE20040757A1 (pl)
PL (1) PL211057B1 (pl)
PT (1) PT1506179E (pl)
RS (1) RS51042B (pl)
TN (1) TNSN04225A1 (pl)
TW (1) TWI258479B (pl)
UA (1) UA76877C2 (pl)
UY (1) UY27803A1 (pl)
WO (1) WO2003095434A1 (pl)
ZA (1) ZA200408783B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
UA76877C2 (uk) * 2002-05-13 2006-09-15 Ф.Хоффманн-Ля Рош Аг Похідні бензоксазину як 5-нт6 модулятори і їх застосування
PT1562918E (pt) 2002-11-08 2008-03-12 Hoffmann La Roche Benzoxazinonas substituídas e as suas utilizações
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
AU2004299201B2 (en) * 2003-12-09 2009-12-03 F. Hoffmann-La Roche Ag Benzoxazine derivatives and uses thereof
AU2005205016B2 (en) * 2004-01-16 2010-07-15 F. Hoffmann-La Roche Ag 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system
RU2372344C2 (ru) * 2004-05-05 2009-11-10 Ф. Хоффманн-Ля Рош Аг Арилсульфонилбензодиоксаны, применяемые для модуляции 5-нт6 рецептора, 5-нт2a рецептора или и того, и другого
AU2005291541B2 (en) * 2004-09-30 2011-03-10 F. Hoffmann-La Roche Ag Benzoxazine and quinoxaline derivatives and uses
US7378415B2 (en) * 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1799306B1 (en) * 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
AR078770A1 (es) * 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
KR101293384B1 (ko) * 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US9403800B2 (en) * 2012-01-24 2016-08-02 Chemregen, Inc. Compounds for inhibition of cancer cell proliferation
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029479C (zh) * 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5492914A (en) * 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
AU732863B2 (en) 1997-04-18 2001-05-03 Smithkline Beecham Plc Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
IL133870A0 (en) 1997-07-11 2001-04-30 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
JP2003524571A (ja) * 1997-07-25 2003-08-19 ハー・ルンドベック・アクチエゼルスカベット インドール−及び２，３−ジヒドロインドール誘導体、その製造方法及びその使用方法
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
JP2003521443A (ja) * 1998-06-19 2003-07-15 ハー・ルンドベック・アクチエゼルスカベット ４，５，６及び７−インドール及びインドリン誘導体、その製造方法及びその使用方法
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
NZ517900A (en) * 1999-08-23 2003-08-29 Solvay Pharm Bv Phenylpiperazines useful as serotonin reuptake inhibitors
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1255743A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
UA76877C2 (uk) * 2002-05-13 2006-09-15 Ф.Хоффманн-Ля Рош Аг Похідні бензоксазину як 5-нт6 модулятори і їх застосування

Also Published As

Publication number Publication date
US20050130962A1 (en) 2005-06-16
US20130123251A1 (en) 2013-05-16
MXPA04011254A (es) 2005-01-25
TWI258479B (en) 2006-07-21
US20030232825A1 (en) 2003-12-18
AU2003233231A1 (en) 2003-11-11
JP4307377B2 (ja) 2009-08-05
CN100429206C (zh) 2008-10-29
DE60303376D1 (de) 2006-04-13
MA27118A1 (fr) 2004-12-20
JP2005530774A (ja) 2005-10-13
CN1653054A (zh) 2005-08-10
HRP20041030A2 (en) 2005-06-30
IL164928A0 (en) 2005-12-18
KR100636475B1 (ko) 2006-10-18
ES2256744T3 (es) 2006-07-16
UA76877C2 (uk) 2006-09-15
DK1506179T3 (da) 2006-06-06
HK1080846A1 (zh) 2006-05-04
EP1506179A1 (en) 2005-02-16
NZ536230A (en) 2007-05-31
TNSN04225A1 (fr) 2007-03-12
PT1506179E (pt) 2006-06-30
UY27803A1 (es) 2003-11-28
GT200300108A (es) 2004-03-15
PL211057B1 (pl) 2012-04-30
AR039988A1 (es) 2005-03-09
CA2485136A1 (en) 2003-11-20
PE20040757A1 (es) 2004-11-06
US8377931B2 (en) 2013-02-19
JO2413B1 (en) 2007-11-11
BR0310032A (pt) 2005-02-15
TW200400188A (en) 2004-01-01
PA8573501A1 (es) 2003-12-10
US20090325950A1 (en) 2009-12-31
EA200401455A1 (ru) 2005-06-30
BRPI0310032B8 (pt) 2021-05-25
NO329380B1 (no) 2010-10-04
AU2003233231B2 (en) 2009-02-26
ZA200408783B (en) 2005-12-28
US6867204B2 (en) 2005-03-15
ECSP045420A (es) 2005-01-03
BRPI0310032B1 (pt) 2019-01-08
RS51042B (sr) 2010-10-31
KR20040106538A (ko) 2004-12-17
HRP20041030B1 (hr) 2013-03-31
RS97004A (sr) 2006-10-27
DE60303376T2 (de) 2006-11-16
WO2003095434A1 (en) 2003-11-20
MY139612A (en) 2009-10-30
NO20044665L (no) 2004-12-03
EG25683A (en) 2012-05-16
CA2485136C (en) 2011-12-20
ATE316523T1 (de) 2006-02-15
EP1506179B1 (en) 2006-01-25
EA009982B1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
BG107171A (bg) Производни на пурин
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
SE0302760D0 (sv) New compounds
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
PA8621501A1 (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
MY136824A (en) Substituted benzoxazinones and uses thereof
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
MY138826A (en) 2,7-substituted indoles
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
DK1406902T3 (da) Hexahydroazepino[4,5-g]indoler og -indoliner som 5-HT-receptor-ligander
PL1831191T3 (pl) Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
DE602004016177D1 (de) Methylindole und methylpyrrolopyridine als alpha-1-adrenerge agonisten
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators
MXPA05010650A (es) Pirazoles sustituidos.

Legal Events

Date Code Title Description
T3 Translation of ep patent
RECP Rectifications of patent specification